Infectious Disease Department, UMR 1173, Versailles Saint-Quentin University, Versailles, France.
Infectious Disease Department, Raymond Poincaré Paris Saclay University Hospital, Garches, France.
J Antimicrob Chemother. 2023 May 3;78(5):1211-1218. doi: 10.1093/jac/dkad070.
While the treatment of ESBL-producing Enterobacterales osteomyelitis relies on carbapenems, the optimal regimen for OXA48 types remains unclear. We evaluated the efficacy of ceftazidime/avibactam in different combinations in an experimental model of OXA-48-/ESBL-producing Escherichia coli osteomyelitis.
E. coli pACYC184 is a clinical strain harbouring blaOXA-48 and blaCTX-M-15 inserts, with 'increased exposure susceptibility' to imipenem (MIC, 2 mg/L), gentamicin (MIC, 0.5 mg/L), colistin (MIC, 0.25 mg/L), ceftazidime/avibactam (MIC, 0.094 mg/L) and fosfomycin (MIC, 1 mg/L), and resistance to ceftazidime (MIC, 16 mg/L). Osteomyelitis was induced in rabbits by tibial injection of 2 × 108 cfu of OXA-48/ESBL E. coli. Treatment started 14 days later for 7 days in six groups: (1) control, (2) colistin 150.000 IU/kg subcutaneously (SC) q8h, (3) ceftazidime/avibactam 100/25 mg/kg SC q8h, (4) ceftazidime/avibactam + colistin, (5) ceftazidime/avibactam + fosfomycin 150 mg/kg SC q12h, (6) ceftazidime/avibactam + gentamicin 15 mg/kg intramuscularly (IM) q24h. Treatment was evaluated at Day 24 according to bone cultures.
In vitro, time-kill curves of ceftazidime/avibactam in combination showed a synergistic effect. In vivo, compared with controls, rabbits treated with colistin alone had similar bone bacterial density (P = 0.50), whereas ceftazidime/avibactam alone or in combinations significantly decreased bone bacterial densities (P = 0.004 and P < 0.0002, respectively). Bone sterilization was achieved using ceftazidime/avibactam in combination with colistin (91%) or fosfomycin (100%) or gentamicin (100%) (P < 0.0001), whereas single therapies were not different from controls. No ceftazidime/avibactam-resistant strains emerged in rabbits treated, regardless of the combination.
In our model of E. coli OXA-48/ESBL osteomyelitis, ceftazidime/avibactam in combination was more effective than any single therapy, whatever the companion drug used (gentamicin or colistin or fosfomycin).
虽然产 ESBL 肠杆菌科骨髓炎的治疗依赖于碳青霉烯类药物,但对于 OXA48 型的最佳治疗方案仍不清楚。我们评估了头孢他啶/阿维巴坦不同组合在产 OXA-48-/ESBL 大肠埃希菌骨髓炎实验模型中的疗效。
E. coli pACYC184 是一株含有 blaOXA-48 和 blaCTX-M-15 插入物的临床菌株,对亚胺培南(MIC,2 mg/L)、庆大霉素(MIC,0.5 mg/L)、多粘菌素(MIC,0.25 mg/L)、头孢他啶/阿维巴坦(MIC,0.094 mg/L)和磷霉素(MIC,1 mg/L)的“增加暴露易感性”,对头孢他啶(MIC,16 mg/L)耐药。通过胫骨注射 2×108 cfu 产 OXA-48/ESBL 大肠埃希菌在兔中诱导骨髓炎。在 14 天后开始治疗 7 天,分为 6 组:(1)对照组,(2)多粘菌素 150000 IU/kg 皮下(SC)q8h,(3)头孢他啶/阿维巴坦 100/25 mg/kg SC q8h,(4)头孢他啶/阿维巴坦+多粘菌素,(5)头孢他啶/阿维巴坦+磷霉素 150 mg/kg SC q12h,(6)头孢他啶/阿维巴坦+庆大霉素 15 mg/kg 肌肉注射(IM)q24h。根据骨培养在第 24 天评估治疗效果。
体外,头孢他啶/阿维巴坦联合用药的时间杀菌曲线显示协同作用。在体内,与对照组相比,单独使用多粘菌素的兔子的骨细菌密度相似(P=0.50),而单独使用头孢他啶/阿维巴坦或联合用药显著降低骨细菌密度(P=0.004 和 P<0.0002,分别)。头孢他啶/阿维巴坦联合多粘菌素(91%)或磷霉素(100%)或庆大霉素(100%)可实现骨杀菌(P<0.0001),而单一治疗与对照组无差异。无论联合用药如何,接受治疗的兔子中均未出现头孢他啶/阿维巴坦耐药株。
在我们的产 OXA-48/ESBL 大肠埃希菌骨髓炎模型中,头孢他啶/阿维巴坦联合用药比任何单一治疗都更有效,无论使用哪种联合药物(庆大霉素或多粘菌素或磷霉素)。